Johnson & Johnson (NYSE: JNJ) reported its third quarter 2025 earnings results today. Reported sales increased 6.8% year-over-year to $24 billion. Operational
JNJ Earnings: Key quarterly highlights from Johnson & Johnson’s Q3 2025 financial results
Categories
Health Care
Our differentiation is validated by strong, sustainable unit economics: Prenetics CEO
Prenetics Global Limited (NASDAQ: PRE), headquartered in Hong Kong, is a health sciences company active in genomics, diagnostics, and consumer health. In
Innovation pipeline, portfolio in focus ahead of Johnson & Johnson’s Q3 earnings
For Johnson & Johnson (NYSE: JNJ), 2025 has been a strong year, marked by an impressive financial performance that drove the stock
Earnings Summary: AngioDynamics (ANGO) reports Q1 loss; sales up 12.2%
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Thursday reported a net loss for the first quarter of 2026. Revenues increased 12.2%
McKesson Corporation (MCK) raises FY26 earnings guidance
McKesson Corporation (NYSE: MCK), a diversified healthcare service company that operates in partnership with biopharma companies and care providers, has published its
Inspire Veterinary Partners has a focus on long-term relationship with stakeholders: CEO
Inspire Veterinary Partners (NASDAQ: IVP) operates a growing network of veterinary hospitals across the US, specializing in small animal care for companion
Earnings Summary: Agilent (A) reports higher Q3 2025 revenue and profit
Healthcare company Agilent Technologies Inc. (NYSE: A) has reported higher revenue and adjusted earnings for the third quarter of fiscal 2025. The
Earnings Summary: A snapshot of CooperCompanies’ (COO) Q3 2025 report
Medical device maker CooperCompanies (NYSE: COO) has reported a double-digit increase in adjusted earnings for the third quarter of 2025 amid strong
IPO News: Picard Medical files for US IPO amid growth push
After a modest start to the year, IPO activity gained momentum in the second quarter, despite lingering macro headwinds and policy uncertainty.
MDT Earnings: Medtronic Q1 2026 adj. profit rises on higher sales
Medical device maker Medtronic plc (NYSE: MDT) on Tuesday reported an increase in net sales and adjusted earnings for the first quarter
Earnings Summary: Cardinal Health reports higher Q4 earnings and flat revenues
Cardinal Health (NYSE: CAH), a leading pharmaceuticals distributor, on Tuesday reported an increase in adjusted profit for the fourth quarter of 2025.
Key highlights from Eli Lilly’s (LLY) Q2 2025 earnings results
Eli Lilly and Company (NYSE: LLY) reported its second quarter 2025 earnings results today. Worldwide revenue was $15.56 billion, up 38% from
Strategic partnerships have been essential to Profusa’s progress: CEO Ben Hwang
Profusa, Inc. (NASDAQ: PFSA) is a digital health company pioneering a new generation of biointegrated sensors. Its injectable biosensors are designed to
Eli Lilly (LLY) set to report Q2 2025 results. Here’s what to expect
Eli Lilly and Company (NYSE: LLY) had a positive start to fiscal 2025, reporting strong revenue and earnings growth for the first
PFE Earnings: All you need to know about Pfizer’s Q2 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its second quarter 2025 earnings results today. Revenues were $14.7 billion, up 10% year-over-year. Reported net income
Earnings Summary: IDEXX Q2 2025 profit rises on higher revenues
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a leading pet healthcare company, on Monday reported an increase in revenue and net income for the
BIIB Earnings: Highlights of Biogen’s Q2 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) on Thursday reported higher revenues and adjusted profit for the second quarter of 2025. The company
Key highlights from AbbVie’s (ABBV) Q2 2025 earnings results
AbbVie (NYSE: ABBV) reported its second quarter 2025 earnings results today. Worldwide net revenues were $15.4 billion, up 6.6% on a reported
Bristol Myers Squibb (BMY) Earnings: 2Q25 Key Numbers
Bristol Myers Squibb (NYSE: BMY) reported its second quarter 2025 earnings results today. Total revenues inched up 1% year-over-year to $12.3 billion.
MRK Earnings: Merck & Co Q2 adj. profit drops on lower sales
Merck & Co. Inc. (NYSE: MRK) on Tuesday reported lower sales and adjusted earnings for the second quarter of 2025. The company
Key highlights from UnitedHealth Group’s (UNH) Q2 2025 earnings results
UnitedHealth Group (NYSE: UNH) reported its second quarter 2025 earnings results today. Total revenues were $111.6 billion compared to $98.8 billion in